TE与TEC新辅助化疗方案对乳腺癌的近期疗效和不良反应观察

目的：观察TE与TEC两种新辅助化疗方案对乳腺癌的近期疗效和不良反应。方法：选择2012年8月-2013年10月我院收治Ⅱ-Ⅲ期女性原发性乳腺癌患者167例，按照新辅助化疗方案分为两组，TE组85例和TEC组82例，其中（1）TE方案：多西他赛75mg／m2＋表柔比星50mg／m2，第1天静脉滴注，1个周期为21d；（2）TEC方案：多西他赛75mg／m2＋表柔比星50mg／m2＋环磷酰胺500mg／m2，第1天静脉滴注，1个周期为21d；两组化疗方案均行4个周期，评价两组患者的近期疗效和不良毒副反应。结果：TE组与TEC组临床疗效相比差异无统计学意义（P〉0．05）；两组患者中性粒细胞减少发生率（37．6％US．58．8％）具有统计学差异（χ9．001，P〈0．05）；在血小板、血红蛋白、胃肠道反应、肝功能异常、心脏毒性及脱发不良毒副反应方面差异无统计学意义（P〉0．05）。结论：在Ⅱ-Ⅲ期乳腺癌患者新辅助化疗中，TE与TEC方案近期疗效相似，但中性粒细胞减少的发生率TEC方案明显高于TE方案。

Short-term efficacy and adverse reaction of neoadjuvant chemotherapy of TE and TEC in breast cancer patients

Objective： To observe the short-term efficacy and adverse reaction of neoadjuvant chemotherapy of TE and TEC in breast cancer patients. Methods： A total of 167 female cases at stage I] - HI with primary breast cancer were selected, they were divided into TE group of 85 cases and 82 cases in TEC group according to the new adjuvant chemotherapy. In TE group, patients were treated with 75mg/m2 ：Docetaxel epirubicin 50mg/m2, section 1D, intravenous drip, 1 cycles for 21d; TEC group, patients were treated with 75mg/m2 ：Docetaxel epirubicin cyclophosphamide than star 50mg/m2 q- 500mg/m2, section 1D, intravenous drip, 1 cycles for 21d; two groups underwent 4 cycles of chemotherapy. Curative effect of two groups and adverse effect was compared. Results： There was no significant difference in clinical therapeutic effect between TE group and TEC group （P〉0.05）. In neutropenia incidence rate was 37.6% and 58.8%, with statistical significant difference （χ2 = 9. 001, P〈0.05）. But there was no significant difference in platelet, hemoglobin, gastrointestinal reaction, liver dysfunction, heart, toxicity and alopecia adverse side effects （P〉0.05）. Conclusion： TE and TEC has the similar efficacy in treating breast cancer patients at stage Ⅱ ∽Ⅲ, and neutropenia incidence rate of TEC scheme is significantly higher than that of TE scheme.